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atthew E. Wiisanen, MD, Ahmed Abdel-Latif, MD, MSPH, Debabrata Mukherjee, MD,
haled M. Ziada, MD
exington, Kentucky
bjectives We sought to review the published data and perform a meta-analysis to reach robust
onclusions in the comparison between bare-metal stents (BMS) and drug-eluting stents (DES) in
aphenous vein graft (SVG) percutaneous coronary interventions (PCIs).
ackground Drug-eluting stents are superior to BMS in reducing major adverse cardiac events
MACE) after PCI in native coronary arteries. However, studies comparing BMS with DES in PCI of
VG have had mixed results, probably due to smaller numbers and the nonrandomized nature of
ost of them.
ethods The published reports search identiﬁed 4 randomized controlled trials and 19 cohort stud-
es comparing BMS with DES in SVG interventions. Clinical end point data were abstracted and ana-
yzed in aggregate and in subgroup analyses with random-effects model.
esults Patients receiving DES had a lower risk of mortality (odds ratio [OR]: 0.75; conﬁdence inter-
al [CI]: 0.59 to 0.96), target lesion revascularization (TLR) (OR: 0.57; CI: 0.40 to 0.82), target vessel
evascularization (TVR) (OR: 0.56; CI: 0.40 to 0.77), and MACE (OR: 0.61; CI: 0.42 to 0.79). Drug-eluting
tent use resulted in a signiﬁcant absolute risk reduction in TLR (0.07; CI: 0.11 to 0.03), TVR
0.10; CI: 0.15 to 0.05), and MACE (0.12; CI: 0.18 to 0.06). There was no signiﬁcant differ-
nce between the groups in recurrent myocardial infarction (OR: 0.99; CI: 0.65 to 1.51) or stent
hrombosis (OR: 0.78; CI: 0.40 to 1.52).
onclusions In this meta-analysis comparing DES with BMS use in PCI of SVG lesions, DES use was
ssociated with improved mortality, MACE, TLR, and TVR. There was no evidence of increased risk of
yocardial infarction or stent thrombosis. (J Am Coll Cardiol Intv 2010;3:1262–73) © 2010 by the
merican College of Cardiology Foundation
rom the Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky. Michael
utcher, MD, served as Guest Editor for this paper. All authors have reported that they have no relationships to disclose.anuscript received March 28, 2010; revised manuscript received August 18, 2010, accepted August 30, 2010.
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1263ercutaneous revascularization procedures of saphenous
ein graft (SVG) lesions are associated with a higher risk
f complications (1), despite major advances in pharma-
ological and device therapy. Compared with balloon
ngioplasty alone, use of bare-metal stents (BMS) for
reatment of SVG lesions resulted in significant reduction
n major adverse events, including need for repeat revas-
ularization (2). Embolism protection devices have sig-
ificantly reduced acute morbidity and mortality (3,4).
onetheless, restenosis at the target lesion as well as
evelopment of new lesions underlie the higher rates of
ong-term graft failure after percutaneous coronary inter-
ention (PCI) (5–8).
Drug-eluting stents (DES) have decreased the reste-
osis rates after native coronary interventions and, al-
hough not approved for such indications, have been
idely used for treatment of SVG lesions (9–11). How-
ver, the superiority of DES over BMS in SVG lesions
as not been clearly established. Data emerging from
omparative studies have been mixed. Most such com-
arisons were retrospective in nature and included a
elatively small number of patients. In this meta-analysis,
e report the compilation of the clinical outcomes data
hat exists from both randomized controlled trials
RCTs) and retrospective comparative studies looking at
he differences between BMS and DES in the treatment
f SVG obstructive lesions.
ethods
eview question and study protocol. The review sought to
nswer the following question: Does the use of DES in
VG interventions reduce periprocedural and long-term
linical events when compared with use of BMS? We
eport this protocol-driven systematic review according to
he MOOSE (Meta-analysis Of Observational Studies in
pidemiology) (12) and QUOROM (Quality of Report-
ng of Meta-analysis) (13) statements.
ligibility criteria. Two reviewers (M.E.W. and A.A.L.)
udged eligibility of studies in duplicate and indepen-
ently. Eligible studies were RCTs and cohort studies
xamining the use of DES versus BMS during SVG
nterventions. We included studies that used historic
ontrols, but we performed a subgroup analysis to iden-
ify the significance of this methodology, because this
raditionally favors new therapies (14). We excluded
tudies that reported only intravascular ultrasound and
uantitative coronary angiography data and did not
iscern the clinical outcomes examined in the meta-
nalysis. Similarly, studies that did not include a control
rm were excluded.
earch strategy. We searched MEDLINE (January 1980
o December 2009), the Cochrane databases (December
009), EMBASE (January 1980 to December 2009), bINAHL (January 1982 to December 2009), the U.S.
ood and Drug Administration website, and BIOSIS
reviews (January 1980 to December 2009) with
atabase-appropriate MESH terms for the following:
ercutaneous coronary intervention, balloon angioplasty,
tenting, saphenous venous grafts, coronary artery bypass
raft, and clinical outcomes. We sought additional stud-
es by reviewing the reference lists of eligible studies and
elevant review articles. The complete search strategy is
vailable upon request from the authors.
ata abstraction. Two reviewers (M.E.W. and A.A.L.)
orking in duplicate and independently used a standard-
zed form to abstract the data from each study. The
uthor K.M.Z. solved disagree-
ents that could not be solved
y consensus. When necessary,
ajor adverse cardiac events
MACE) were calculated by
umming the reported individual
nd points if MACE was not
pecifically reported in the pub-
ished report.
uality assessment. We used
he criteria by Juni et al. (15) to
scertain the methodological
uality of included randomized
rials and a modified Newcastle-
ttawa scale (16) to assess the
uality of cohort studies (details
ncluded in Online Appendix).
ata analysis. META-ANALYSES.
he main outcomes of our re-
iew were all-cause mortality,
arget lesion revascularization
TLR), target vessel revascular-
zation (TVR), MACE, myo-
ardial infarction (MI), and
tent thrombosis (ST). We used
he abstracted MACE as de-
ned by the authors; however,
he definition varied among
tudies. For mortality, some studies used all-cause mortality
17–27), whereas others used cardiac mortality (28–32).
ome studies used TVR (20–22,24–27,29,32–35), whereas
thers used TLR (28,30,31,36) or both (18–20,24,37) in
heir composite MACE end point. When MACE was
ot specified in the original article, we calculated MACE
s the sum of all-cause mortality, nonfatal MI, and
VR/TLR. Given the observed heterogeneity in the
ethodologies of the studies and the types of stents used,
e conducted random-effects meta-analyses to pool these
utcomes across included studies, estimating the odds
atios (ORs) of the pre-specified clinical end points
Abbreviations
and Acronyms
ARR  absolute risk
reduction
BMS  bare metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
EPD  embolism protection
device
MACE  major adverse
cardiac events
MI  myocardial infarction
NNT  numbers needed to
treat
OR  odds ratio
PCI  percutaneous
coronary intervention
RCT  randomized
controlled trial
ST  stent thrombosis
SVG  saphenous vein graft
TLR  target lesion
revascularization
TVR  target vessel
revascularizationetween DES- and BMS-treated patients and their
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1264ssociated 95% confidence interval (CI). The OR is a way
f comparing whether the probability of death, TLR,
VR, MACE, recurrent MI, or ST is the same between
ES-treated patients and BMS-treated patients. We also
alculated the absolute risk reduction (ARR) (i.e., risk
ifference) and the “numbers needed to treat” (NNT) to
ssess the clinical significance of the outcome. The ARR
ignifies the absolute difference in outcome rates between
he DES-treated and BMS-treated groups. The ORs
rom separate studies were combined according to
andom-effects model (Mantel-Haenszel method)
38,39). The NNT is the reciprocal of the ARR and
enotes the number of patients that would need to be
reated with DES to prevent 1 adverse outcome. We
eported the outcomes from RCTs and cohort studies
eparately as well as the combined outcomes from all the
ncluded studies. We estimated the proportion of
etween-study inconsistency due to true differences be-
ween studies (rather than differences due to random
rror or chance) with the I2 statistic (40), with values of
5%, 50%, and 75% considered low, moderate, and high,
espectively. Funnel plots graphically explored publica-
ion bias. The Review Manager software (RevMan ver-
ion 4.3. Copenhagen, The Nordic Cochrane Centre,
he Cochrane Collaboration, 2006) was used for the
nalysis.
UBGROUP ANALYSES. We conducted planned subgroup
(revi
480 reports identified
by initial search
73 reports reviewed
12 r
not 
61 reports examined in detail
23 studies  (4 RCTs and 19 cohorts) include
meta-analysis
40 r
cont
clini
of D
data
Figure 1. Selection of Trials for Inclusion in Meta-Analysis
Selection of trials for inclusion in meta-analysis. The initial search identiﬁed 48
included in the ﬁnal analysis. DES  drug-eluting stent(s); RCT  randomizednalyses and tested for treatment–subgroup interactions. slanned subgroups comprised the types of study design
RCTs vs. cohort studies); the use of historical versus
oncurrent controls; and the frequency of distal embolic
rotection device (EPD) use (above and below the
edian).
esults
earch results. Of 480 articles retrieved during the initial
earch (Fig. 1), 407 articles were not reports of original
nvestigations (review articles and editorials), 12 studies
ere not pertinent to the study question (studies of
PDs, covered stents, and brachytherapy), and 40 other
tudies were further excluded (35 were either case reports
r case series without a control group, 2 studies did not
eport relevant clinical end point data pre-specified in our
nclusion criteria, 1 study compared DES sub-types, 1
id not include SVG data, and 1 study was a subgroup
nalysis). Twenty-three studies (4 RCTs, 19 cohort
tudies) with a total of 5,324 patients (2,805 received
ES and 2,519 received BMS) were eligible for review.
he inter-reviewer agreement on study eligibility was
00%.
tudy characteristics. Table 1 summarizes the clinical char-
cteristics, and Table 2 summarizes the angiographic/
rocedural characteristics of the included studies (41–
4). Target vessel diameter and lesion length were not
ports excluded
icles and editorials)
 excluded because the study question was 
nt to the meta-analysis.
e 
 excluded: because of lack of a 
up (35 reports); no report of relevant 
d point data (2 reports); comparison 
btypes (1 report) ; no report of SVG 
ort); subgroup analysis (1 report).
les, of which, 23 studies (4 randomized controlled and 19 cohorts) were
lled trial; SVG  saphenous vein graft.407 re
ew art
eports
pertine
d in th
eports
rol gro
cal en
ES-su
 (1 rep
0 articpecified in every study, but stent diameter and stent
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1265ength were reported. Notably, the sample size in each
tudy was relatively small (range 39 to 482 patients;
edian 113 patients), and the follow-up duration ranged
rom 6 to 48 months (median 18 months). There was
Table 1. Clinical Characteristics of Included Studies
Study Design
Study
Period Controls
RCTs
Brilakis et al. (29) RCT 2005–2007 Contemporary
Jeger et al. (32) RCT 2003–2004 Contemporary
Vermeersch et al. (26) RCT 2003–2004 Contemporary
Vermeersch et al. (41) RCT 2003–2006 Contemporary
Cohort nonrandomized trials
Assali et al. (33) Cohort 2003–2005 Historical
Bansal et al. (28) Cohort 2003–2005 Contemporary
Brodie et al. (17) Cohort 2003–2006 Contemporary
Chu et al. (18) Cohort 2001–2004 Historical
Ellis et al. (42) Cohort 2000–2003 Historical
Ge et al. (43) Cohort 2002–2004 Historical
Gioia et al. (30) Cohort 2002–2006 Contemporary
Goswami et al. (31) Cohort 2003–2007 Contemporary
Hoffman et al. (19) Cohort 2002–2004 Contemporary
Kaplan et al. (20) Cohort 2003–2006 Contemporary
Lee et al. (21) Cohort 2003–2004 Contemporary
Lozano et al. (44) Cohort NR Historical
Minutello et al. (22) Cohort 2003–2005 Historical
Okabe et al. (23) Cohort 2000–2006 Historical and contemporary
Ramana et al. (24) Cohort 2003–2007 Contemporary
Shishehbor et al. (36) Cohort 2000–2007 Historical and contemporary
van Twisk et al. (25) Cohort 2000–2005 Historical
Vignali et al. (35) Cohort 2003–2006 Contemporary
Wohrle et al. (27) Cohort 2005–2005 Historical
BMS bare metal stent(s); DES drug-eluting stent(s); NR not reported; RCT randomized cononsiderable heterogeneity in the use of EPD, which ianged widely from 1.6% to 100% (median 43%). The
verage age of the graft reflected the clinical practice
range 7.5 to 12.4 years; median 11 years).
tudy quality. Online Table 1 describes the methodolog-
ample Size
Average Patient Age
(yrs)
Length of
Follow-Up
(Months)
Mandated Angiographic
Follow-Up
(Y/N)
39
41
BMS 67 9
DES 66 9
18 Y
13
34
71 8 18 N
37
38
BMS 72 8
DES 73 7
6 Y
37
38
BMS 72 8
DES 73 7
BMS 32
DES 31
N
43
68
BMS 71 9
DES 70 8
NR N
72
37
BMS 64.9 1.1
DES 68.0 1.6
33 N
343
785
BMS 68.8 10.2
DES 67.5 10.3
24 N
57
48
BMS 71.4 9.9
DES 68.6 10.2
12 N
175
175
BMS 68.5 10.0
DES 69.8 9.0
NR N
89
61
BMS 67 8
DES 67 8
6 Y
119
106
BMS 70 7
DES 71 8
BMS 16
DES 16
N
95
284
BMS 69.5 10.4
DES 70.7 9.7
30 N
60
60
BMS 67 7
DES 67 11
6 Y
33
37
BMS 70.5 8.7
DES 72.3 9.0
NR N
84
139
BMS 69.4 11.2
DES 68.6 10.5
NR Y
114
98
BMS 66.4 9
DES 70.6 8.9
30 N
50
59
BMS 69.4 11.0
DES 70.8 12.7
BMS 20 16
DES 20 12
N
334
138
BMS 70 11
DES 70 11
12 N
170
141
BMS 69.1
DES 70.0
BMS 36.2
DES 31.0
N
pre-2003: 239
post-2003: 110
: 217
BMS pre-2003: 69 9
BMS post-2003: 68 10
DES: 70 10
35 N
128
122
BMS 69.3
DES 68.3
48 N
288
72
BMS 71.4 8.6
DES 72.5 7.8
14 N
26
13
BMS 69.6 6.4
DES 70.7 4.1
NR Y
trial.S
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
DES
BMS
BMS
DES
BMS
DES
BMS
DES
BMS
DEScal quality of the RCTs, and Online Table 2 describes
t
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1266he quality of the cohort studies. All cohort studies and at
east 1 RCT failed to blind participants and caregivers,
Table 2. Angiographic/Procedural Characteristics of Included Studies
Type of DES Used
EPD Use
(%)
RCTs
Brilakis et al. (29) Paclitaxel 54
Jeger et al. (32) Sirolimus and
paclitaxel
NR
Vermeersch et al. (26) Sirolimus BMS 84
DES 79
Vermeersch et al. (41) Sirolimus BMS 84
DES 79
Cohort nonrandomized trials
Assali et al. (33) Sirolimus and
paclitaxel
BMS 48
DES 38
Bansal et al. (28) Sirolimus (95%) BMS 27
DES 39
Brodie et al. (17) Sirolimus, paclitaxel BMS 33.7
DES 37.3
Chu et al. (18) Sirolimus BMS 100
DES 100
Ellis et al. (42) Sirolimus BMS 25.1*
DES 35.1
Ge et al. (43) Sirolimus and
paclitaxel
BMS 22.5
DES 31.1
Gioia et al. (30) Sirolimus, paclitaxel,
tacrolimus
BMS 21
DES 26
Goswami et al. (31) Sirolimus, paclitaxel NR
Hoffman et al. (19) Paclitaxel BMS 47
DES 52
Kaplan et al. (20) NR BMS 33.3
DES 27
Lee et al. (21) Paclitaxel, sirolimus BMS 19
DES 15
Lozano et al. (44) Paclitaxel, sirolimus,
zotarolimus,
other
BMS 5
DES 10
Minutello et al. (22) Sirolimus BMS 48*
DES 71.2
Okabe et al. (23) Sirolimus and
paclitaxel
BMS 26
DES 21
Ramana et al. (24) Sirolimus NR
Shishehbor et al. (36) Sirolimus and
paclitaxel
BMS pre-2003: 16
BMS post-2003: 62
DES 56
van Twisk et al. (25) Sirolimus and
paclitaxel
NR
Vignali et al. (35) Sirolimus, paclitaxel NR
Wohrle et al. (27) Paclitaxel BMS 54
DES 85
*Statistical significant difference with p 0.05. †Reference vessel diameter, not stent diameter.
EPD embolic protection device; IQR interquartile range; other abbreviations as in Table 1.nd at least 1 RCTs and 11 cohort studies failed to blind autcome assessors. The follow-up was complete in all
CTs and 12 of the 16 cohorts. The inter-reviewer
rage Stent Length
(mm)
Average Vessel or
Stent Diameter
(mm)
Average Graft Age
(yrs)
29 16
8 17
BMS 3.17 0.42
DES 3.14 0.35
BMS 12 6
DES 11 6
46 30
1 25
BMS 17% 3.5
DES 29% 3.5
NR
33.4 18.2
6.9 17.6
BMS 3.36 0.26
DES 3.41 0.19
BMS 12.6 5.9
DES 12.4 4.6
33 18
7 18
BMS 3.36 0.26
DES 3.41 0.19
BMS 12.6 5.9
DES 12.4 4.6
20.7 13.1*
0.3 18.5
BMS 3.6 0.7*
DES 3.3 0.4
BMS 11.4 4.5
DES 10.8 5.1
17.9 0.76
7.1 1.0
BMS 3.8 0.07*
DES 3.0 0.07
NR
22.0 12.2
5.0 15.4
BMS 3.7 0.8*†
DES 3.3 0.5
BMS 68.8 10.2
DES 67.5 10.6
23.1 10.6
0.8 7.5
BMS 3.8 0.8*
DES 3.1 0.4
BMS 9.4 6.0
DES 10.1 7.6
21.6 11.8
0.6 8.1
BMS 3.37 0.37†
DES 3.33 0.34
BMS 9.8 6.4
DES 10.0 6.2
20.4 8.8*
9.4 19.8
BMS 3.83 0.58*
DES 3.35 0.39
BMS 9.2 4.8
DES 9.7 5.6
24 10
1 6
BMS 3.9 0.5*
DES 3.3 0.4
BMS 11 5
DES 11 6
30.4 22.2
7.9 16.3
BMS 4.4 0.7*
DES 3.3 0.4
NR
14.6 4.4
16.7 3.7
BMS 3.06 0.6†
DES 3.05 0.52
BMS 10.1 4.5
DES 11.3 5.7
15.6 4.5*
18.9 7.4
BMS 3.71 0.54*†
DES 3.42 0.53
BMS 7.6 1.3
DES 7.5 1.3
BMS 2.96 0.65†
DES 2.94 0.23
BMS 7.7 2.8
DES 7.6 3.8
16 5
22.4 13.5
BMS 3.45 0.61*
DES 3.28 0.51
BMS 9.0
DES 10.1
20.8 9.9*
26.1 16.5
BMS 3.43 0.48*
DES 3.12 0.37
NR
19.8 8.6
20.3 6.4
BMS 3.84 2.07*
DES 3.09 0.37
BMS 9.7 6.0
DES 1.04 6.8
29.3
28.3
BMS 4.2*
DES 3.3
BMS 12.9
DES 11.5
BMS pre-2003: 3.4 0.8†
BMS post-2003: 3.9 0.8
DES 3.2 0.5
BMS pre-2003: 9 5
BMS post-2003: 10 6
DES 10 6
31.9 IQR 18.0–40.3*
32.0 IQR 18.0–58.5
BMS 3.5 (IQR 3.3–4.0)*
DES 3.1 (IQR 3.0–3.5)
NR
18.7 6.2
19.7 6.4
BMS 3.5 0.7*
DES 3.0 0.4
NR
23.6 14.1
23 12.4
BMS 3.28 0.82†
DES 3.06 0.7
BMS 9.1 5.1
DES 11.4 7.4Ave
BMS
DES 2
BMS
DES 4
BMS
SES 3
BMS
DES 3
BMS
DES 3
BMS
DES 1
BMS
DES 2
BMS
DES 2
BMS
DES 2
BMS
DES 2
BMS
DES 2
BMS
DES 2
BMS
DES
BMS
DES
NR
BMS
DES
BMS
DES
BMS
DES
BMS
DES
NR
BMS
DES
BMS
DES
BMS
DESgreement on these quality domains was 90%.
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1267eta-analyses. EFFICACY. Compared with BMS-treated
atients, DES-treated patients had a lower incidence of
he pre-specified clinical adverse events. This was dem-
nstrated in the significant reduction in the OR of
ll-cause mortality (OR: 0.72; CI: 0.58 to 0.89), TLR
OR: 0.57; CI: 0.40 to 0.82), TVR (OR: 0.56; CI: 0.40
o 0.77), and MACE (OR: 0.61; CI: 0.47 to 0.79) (Figs. 2–5).
rug-eluting stent use resulted in a significant ARR in
he incidence of TLR (ARR: 0.07; CI: 0.11 to
0.03; NNT: 14), TVR (ARR: 0.10; CI: 0.15 to
0.05; NNT: 10) and MACE (ARR: 0.12; CI: 0.18
o 0.06; NNT: 8) but not in the incidence of all-cause
ortality, MI, or ST (Figs. 6 and 7). The results were
onsistent between the fixed and random effects models.
e drew funnel plots to seek evidence of publication bias
Online Fig. 1): where inconsistency was high, the funnel
lots were not interpretable; where inconsistency was
ow, the funnel plots were inconclusive.
ETEROGENEITY ANALYSIS. Tests for heterogeneity were
Study DES BMS
or subcategory n/N n/N
Brilakis, 2009      5/41               2/39        
Jeger, 2009         1/34               2/13        
Vermeersch, 2006    1/38               0/37        
Vermeersch, 2007    11/38               0/37        
Subtotal (95% CI) 151                126
Total events: 18 (DES), 4 (BMS)
Test for heterogeneity: Chi² = 7.91, df = 3 (P = 0.05), I² = 62.1%
Test for overall effect: Z = 0.82 (P = 0.42)
Assali, 2008        2/68               2/43        
Bansal, 2008        7/37              16/72        
Brodie, 2009        64/785             50/343       
Chu, 2006           3/48               4/57        
Ellis, 2007         8/169              6/169       
Ge, 2005            1/61               2/89        
Gioia, 2008         6/106              7/119       
Goswami, 2009       42/284             12/95        
Kaplan, 2008        1/37               1/33        
Lee, 2005           1/139              3/84        
Lozano, 2009        11/98              15/113       
Minutello, 2007     4/59               6/50        
Okabe, 2008         13/138             40/344       
Ramana, 2008        8/141             21/170       
Shishehbor, 2009    28/217             18/110       
van Twisk, 2008     23/122             34/128       
Vignali, 2008       3/72              22/288       
Whorle, 2006        0/13               0/26        
Subtotal (95% CI) 2594               2333
Total events: 225 (DES), 259 (BMS)
Test for heterogeneity: Chi² = 9.74, df = 16 (P = 0.88), I² = 0%
Test for overall effect: Z = 3.62 (P = 0.0003)
Total (95% CI) 2745               2459
Total events: 243 (DES), 263 (BMS)
Test for heterogeneity: Chi² = 21.05, df = 20 (P = 0.39), I² = 5.0%
Test for overall effect: Z = 3.00 (P = 0.003)
0.1
RCTs
Cohorts
Figure 2. OR of All-Cause Mortality
Forest plot of unadjusted odds ratio (ORs) (with 95% conﬁdence intervals [CIs]
those receiving bare-metal stents (BMS). Signiﬁcant reduction in all-cause mort
Figure 1.one for each of the clinical end points with the I2 ftatistic. There was significant heterogeneity (I2 
2.1%) noted in the all-cause mortality for the RCTs;
owever, the overall I2 statistic was 5%, suggesting that
he OR of 0.72 for DES compared with BMS had little
eterogeneity effect. Overall, however, TVR had a high
2 statistic ( 67.4%), suggesting that most of the
ariability across the studies here was due to heterogene-
ty rather than chance. Target lesion revascularization
nd MACE had relatively high I2 statistics as well (52.8%
nd 68.4%, respectively).
UBGROUP ANALYSES. The treatment effect of DES use
as comparable in all subgroup analyses examined. We
id not find any treatment–subgroup interaction through
ny of our planned subgroup analyses (Online Table 3).
owever, due to the significant heterogeneity in the
tudy designs, some of the comparison arms were unbal-
nced. Of note, all-cause mortality was higher among
CTs, and this is largely influenced by the results of the
ELAYED RRISC (Death and Events at Long-term
OR (random) Weight OR (random)
95% CI % 95% CI
1.56 2.57 [0.47, 14.10]       
0.73 0.17 [0.01, 2.02]        
0.44 3.00 [0.12, 76.03]       
0.55 31.36 [1.77, 555.30]      
3.28 2.33 [0.31, 17.77]
1.14 0.62 [0.08, 4.58]        
4.44 0.82 [0.30, 2.20]        
22.56 0.52 [0.35, 0.77]        
1.88 0.88 [0.19, 4.16]        
3.78 1.35 [0.46, 3.98]        
0.78 0.73 [0.06, 8.18]        
3.50 0.96 [0.31, 2.95]        
8.80 1.20 [0.60, 2.39]        
0.58 0.89 [0.05, 14.80]       
0.88 0.20 [0.02, 1.91]        
6.23 0.83 [0.36, 1.89]        
2.54 0.53 [0.14, 2.01]        
9.50 0.79 [0.41, 1.53]        
5.99 0.43 [0.18, 1.00]        
9.96 0.76 [0.40, 1.44]        
11.26 0.64 [0.35, 1.17]        
2.92 0.53 [0.15, 1.81]        
Not estimable         
96.72 0.69 [0.56, 0.84]
100.00 0.72 [0.58, 0.89]
0.5 1 2 5 10
rs DES Favors BMS
ll-cause mortality in SVG intervention patients receiving DES compared with
OR: 0.72; CI: 0.58 to 0.89; p  0.003) is noted with DES. Abbreviations as in0.2
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1268f restenosis in saphenous vein Grafts with Cypher)
tudy. This difference was minimized by excluding this
tudy. However, this difference is not statistically signif-
cant, whether we included or excluded the DELAYED
RISC study. The studies included were a mixture of
CTs and nonrandomized cohorts. Although the RCTs
emonstrated higher overall all-cause mortality than
ohort studies, there were no appreciable differences in
he other outcomes tested.
AFETY. The use of DES in treatment of SVG lesions
as safe and was not associated with increased compli-
ations. Notably, none of the studies that reported the
ncidence of ST demonstrated significant differences
etween DES- and BMS-treated patients.
iscussion
espite the general agreement on the superiority of DES
ver BMS in reducing clinical end points such as TVR,
LR, and MACE after native vessel PCI, studies com-
aring DES with BMS in SVG interventions have
ielded conflicting results. This systematic review and
omprehensive meta-analysis of the available studies
Study DES BMS
or subcategory n/N n/N
Brilakis, 2009      2/41              11/39        
Vermeersch, 2006    2/38               8/37        
Vermeersch, 2007    9/38              11/37        
Subtotal (95% CI) 117                113
Total events: 13 (DES), 30 (BMS)
Test for heterogeneity: Chi² = 3.95, df = 2 (P = 0.14), I² = 49.4%
Test for overall effect: Z = 2.04 (P = 0.04)
Assali, 2008        7/68              12/43        
Bansal, 2008        11/37              28/72        
Chu, 2006           3/48               4/57        
Ellis, 2007         11/162             16/162       
Ge, 2005            2/61              18/89        
Gioia, 2008         14/106             15/119       
Goswami, 2009       23/284              8/95        
Hoffman, 2007       4/60              13/60        
Kaplan, 2008        2/37              10/33        
Minutello, 2007     8/59              11/50        
Okabe, 2008         13/138             26/344       
Ramana, 2008        10/141             24/170       
Shishehbor, 2009    29/217              7/110       
Vignali, 2008       3/72              23/288       
Subtotal (95% CI) 1490               1692
Total events: 140 (DES), 215 (BMS)
Test for heterogeneity: Chi² = 27.60, df = 13 (P = 0.01), I² = 52.9%
Test for overall effect: Z = 2.42 (P = 0.02)
Total (95% CI) 1607               1805
Total events: 153 (DES), 245 (BMS)
Test for heterogeneity: Chi² = 33.91, df = 16 (P = 0.006), I² = 52.8%
Test for overall effect: Z = 3.03 (P = 0.002)
0.1
RCTs
Cohorts
Figure 3. OR of TLR
Forest plot of unadjusted OR (with 95% CIs) for target lesion revascularization (TLR
Signiﬁcant reduction in TLR (OR: 0.57; CI: 0.40 to 0.82; p  0.002) is noted withemonstrates that DES use is associated with a signifi- aant reduction in adverse clinical end points (TVR, TLR,
ACE, and all-cause mortality). Reassuringly, this im-
rovement has not come with any compromise in safety;
here is no signal of increased MI or ST associated with
ES use.
Currently, the DES has become the mainstay of native
essel PCI, due to the established superiority over BMS
n reducing MACE, primarily by reducing restenosis and
eed for TLR or TVR (45–48). However, studies exam-
ning DES use in SVG interventions were hampered by
he nonrandomized nature and the small numbers in
ost cases. This resulted in conflicting conclusions and a
egree of uncertainty as to whether DES should be used
n SVG interventions. Although many of the early RCTs
howed trends toward improved outcomes with DES over
MS in SVGs, the results from the RRISC study raised
oncerns regarding the potential association with in-
reased mortality in the DES group and attrition of the
mprovement in restenosis after 3 years (41). However, it
s important to note that the small number of patients in
his study did not provide sufficient power to detect true
ffects on morbidity and mortality. In addition, most fatal
OR (random) Weight OR (random)
95% CI % 95% CI
3.66 0.13 [0.03, 0.64]        
3.52 0.20 [0.04, 1.02]        
6.10 0.73 [0.26, 2.05]        
13.28 0.31 [0.10, 0.96]
6.10 0.30 [0.11, 0.83]        
7.21 0.66 [0.28, 1.55]        
3.77 0.88 [0.19, 4.16]        
7.54 0.66 [0.30, 1.48]        
3.93 0.13 [0.03, 0.60]        
7.68 1.06 [0.48, 2.30]        
7.27 0.96 [0.41, 2.22]        
5.25 0.26 [0.08, 0.85]        
3.58 0.13 [0.03, 0.66]        
6.25 0.56 [0.20, 1.51]        
8.27 1.27 [0.63, 2.55]        
7.72 0.46 [0.21, 1.01]        
7.14 2.27 [0.96, 5.36]        
5.03 0.50 [0.15, 1.72]        
86.72 0.62 [0.43, 0.91]
100.00 0.57 [0.40, 0.82]
0.5 1 2 5 10
rs DES Favors BMS
G intervention patients receiving DES compared with those receiving BMS.
Abbreviations as in Figures 1 and 2.0.2
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1269gain emphasizing the limitations of small sample size.
oreover, this mortality difference was not replicated in
ny of the other published RCT or cohort studies. Most
ublished reports in this field (DES in SVG interven-
ions) have similar concerns caused by small sample size.
f note, 11 of the 19 studies included in the analysis
ncluded 150 patients.
The overall mortality rates observed in our analysis (8% to
0%) are similar to those reported in the SVG PCI published
ata (49). Our analysis demonstrated slight albeit statistically
ignificant reduction in mortality among DES-treated pa-
ients. This reduction was not seen in the analysis of the RCTs
even with the exclusion of the DELAYEDRRISC study) but
as evident in the cohort studies. Such difference is likely due
o selection bias in cohort studies. The systematic review by
hishehbor et al. (36) reaches similar conclusions with regard
o potential selection bias in the current era. In that analysis
nd in comparison with BMS use, DES use in SVG interven-
ions was associated with reduced mortality in the era of
outine use of DES (after 2003), but when compared with
MS before 2003 (when DES was not available) that differ-
Study DES BMS
or subcategory n/N n/N
Brilakis, 2009      6/41              12/39        
Jeger, 2009         6/34               6/13        
Vermeersch, 2006    2/38              10/37        
Vermeersch, 2007    13/38              14/37        
Subtotal (95% CI) 151                126
Total events: 27 (DES), 42 (BMS)
Test for heterogeneity: Chi² = 4.32, df = 3 (P = 0.23), I² = 30.6%
Test for overall effect: Z = 2.48 (P = 0.01)
Assali, 2008        10/68              14/43        
Bansal, 2008        13/37              30/72        
Brodie, 2009        144/785             58/343       
Chu, 2006           6/48               6/57        
Ellis, 2007         11/161             19/161       
Ge, 2005            3/61              21/89        
Gioia, 2008         15/106             17/119       
Kaplan, 2008        4/37              11/33        
Lee, 2005           14/139             31/84        
Lozano, 2009        17/98              15/113       
Minutello, 2007     9/59              18/50        
Okabe, 2008         27/138             46/344       
Ramana, 2008        18/141             27/170       
van Twisk, 2008     17/122             36/128       
Vignali, 2008       6/72              32/288       
Whorle, 2006        1/13               9/26        
Subtotal (95% CI) 2085               2120
Total events: 315 (DES), 390 (BMS)
Test for heterogeneity: Chi² = 51.01, df = 15 (P < 0.00001), I² = 70.6%
Test for overall effect: Z = 2.82 (P = 0.005)
Total (95% CI) 2236               2246
Total events: 342 (DES), 432 (BMS)
Test for heterogeneity: Chi² = 58.32, df = 19 (P < 0.00001), I² = 67.4%
Test for overall effect: Z = 3.49 (P = 0.0005)
0.1
RCTs
Cohorts
Figure 4. OR of TVR
Forest plot of unadjusted OR (with 95% CIs) for target vessel revascularization (TV
Signiﬁcant reduction in TVR (OR: 0.56; CI: 0.40 to 0.77; p  0.0005) is noted wince was not observed. tOur stratified analyses demonstrated a reduction in the
enefits observed with DES in longer follow-up trials,
hich is noted on the visual inspection of the forest plots
Online Figs. 2 to 5). Although this reduction is not
onsistent in all the outcomes measured and did not
chieve statistical significance, it is a plausible clinical
ourse. Development of significant focal lesions in SVG
sually indicates a progressive degenerative process that is
ot necessarily stopped by a very focal or segmental
herapy such as stenting. Therefore, future large random-
zed trials with longer follow-up will be required to assess
he durability of the beneficial effects of DES in SVG
rafts.
The use of historical controls in some of the included
tudies (18,22,25,27,33,42) might have influenced the
esults, because this has been shown to favor new
reatments (14). However, stratified analysis excluding
tudies using historical controls showed persistence in the
ignificant reduction in TLR, TVR, and MACE (Online
able 3). By contrast, the reduction in mortality observed
n our analysis is rather small and is probably multifac-
OR (random) Weight OR (random)
95% CI % 95% CI
4.31 0.39 [0.13, 1.16]        
3.30 0.25 [0.06, 1.02]        
2.80 0.15 [0.03, 0.74]        
4.95 0.85 [0.33, 2.20]        
15.36 0.40 [0.19, 0.82]
5.03 0.36 [0.14, 0.90]        
5.50 0.76 [0.33, 1.72]        
7.74 1.10 [0.79, 1.54]        
3.94 1.21 [0.36, 4.04]        
5.71 0.55 [0.25, 1.19]        
3.74 0.17 [0.05, 0.59]        
5.84 0.99 [0.47, 2.09]        
3.73 0.24 [0.07, 0.86]        
6.04 0.19 [0.09, 0.39]        
5.82 1.37 [0.65, 2.91]        
5.08 0.32 [0.13, 0.80]        
6.93 1.58 [0.93, 2.66]        
6.35 0.78 [0.41, 1.47]        
6.36 0.41 [0.22, 0.79]        
5.08 0.73 [0.29, 1.81]        
1.76 0.16 [0.02, 1.41]        
84.64 0.60 [0.42, 0.85]
100.00 0.56 [0.40, 0.77]
0.5 1 2 5 10
rs DES Favors BMS
VG intervention patients receiving DES compared with those receiving BMS.
S. Abbreviations as in Figures 1, 2, and 3.0.2
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1270ignificant reduction in mortality (47,48), and the benefit
bserved in our analysis can be explained at least in part
y the longer duration of dual antiplatelet therapy
50,51). Moreover, selection bias could have contributed
o the reduction in mortality in cohort nonrandomized
tudies (Fig. 2, Online Table 3)
Traditionally, studies that mandate angiographic
ollow-up have reported higher TVR and TLR than
hose that do not, due to the “occulostenotic reflex” (52).
e did not observe significant differences between those
tudies and those that did not mandate the angiographic
ollow-up or the unstratified analysis in the rates of TVR,
LR, or MACE. However, because these are post hoc
nalyses of published data rather than individual patient
ata, and because the influence of performance bias on
he interaction cannot be entirely excluded, larger
ouble-blind RCTs specifically designed to address this
uestion will be necessary.
The use of EPDs was low (median of 38%) in the
tudies we reviewed. This finding is rather concerning,
Study DES BMS
or subcategory n/N n/N
Brilakis, 2009      15/41              19/39        
Jeger, 2009         7/34               8/13        
Vermeersch, 2006    6/38              11/37        
Vermeersch, 2007    22/38              15/37        
Subtotal (95% CI) 151                126
Total events: 50 (DES), 53 (BMS)
Test for heterogeneity: Chi² = 10.06, df = 3 (P = 0.02), I² = 70.2%
Test for overall effect: Z = 1.05 (P = 0.29)
Assali, 2008        14/68              18/43        
Bansal, 2008        17/37              36/72        
Brodie, 2009        239/785            116/343       
Chu, 2006           10/48              10/57        
Ge, 2005            7/61              25/89        
Gioia, 2008         20/106             22/119       
Goswami, 2009       58/284             18/95        
Hoffman, 2007       9/60              22/60        
Kaplan, 2008        4/37              12/33        
Lee, 2005           14/139             31/84        
Minutello, 2007     15/59              25/50        
Okabe, 2008         40/138             81/344       
Ramana, 2008        28/141             47/170       
Shishehbor, 2009    58/217             33/110       
van Twisk, 2008     41/122             67/128       
Vignali, 2008       13/72              58/288       
Whorle, 2006        1/13              10/26        
Subtotal (95% CI) 2387               2111
Total events: 588 (DES), 631 (BMS)
Test for heterogeneity: Chi² = 48.70, df = 16 (P < 0.0001), I² = 67.1%
Test for overall effect: Z = 3.50 (P = 0.0005)
Total (95% CI) 2538               2237
Total events: 638 (DES), 684 (BMS)
Test for heterogeneity: Chi² = 58.77, df = 20 (P < 0.0001), I² = 66.0%
Test for overall effect: Z = 3.67 (P = 0.0002)
0.1
RCTs
Cohorts
Figure 5. OR of MACE
Forest plot of unadjusted OR (with 95% CIs) for major adverse cardiac events (
BMS. Signiﬁcant reduction in MACE (OR: 0.61; CI: 0.47 to 0.79; p  0.0002) is necause the utility of EPD has been well-documented in mhe published data (53) and supported by the guidelines
54). However, we did not observe significant interaction
n the rate of MI or MACE among studies with EPD use
bove or below the median of 38%. This again highlights
he potential of selection bias among the nonrandomized
ohort studies.
The risk of late ST after discontinuation of dual
ntiplatelet therapy has been a major concern about DES
se (48). We did not find higher rates of ST in our
nalysis, which actually trended toward lower ST in the
ES-treated patients. This might be explained by pro-
onged dual antiplatelet therapy in DES-treated patients,
election bias in the cohort studies, and relatively short
ollow-up duration in some of the included studies.
onetheless, “real world” data suggest that with appro-
riate patient selection, the use of DES in SVG inter-
entions is not associated with higher risk of ST.
tudy limitations. Study quality, reliance on retrospective
onrandomized studies, short follow-up duration in most
tudies, and lack of data with the new generation of DES
OR (random) Weight OR (random)
95% CI % 95% CI
4.26 0.61 [0.25, 1.48]        
2.51 0.16 [0.04, 0.65]        
3.33 0.44 [0.14, 1.36]        
4.14 2.02 [0.80, 5.06]        
14.25 0.59 [0.23, 1.57]
4.50 0.36 [0.15, 0.84]        
4.75 0.85 [0.38, 1.88]        
7.66 0.86 [0.65, 1.12]        
3.90 1.24 [0.47, 3.28]        
4.17 0.33 [0.13, 0.83]        
5.41 1.03 [0.52, 2.01]        
5.89 1.10 [0.61, 1.98]        
4.32 0.30 [0.13, 0.74]        
2.88 0.21 [0.06, 0.75]        
5.21 0.19 [0.09, 0.39]        
4.69 0.34 [0.15, 0.76]        
6.74 1.33 [0.85, 2.07]        
6.22 0.65 [0.38, 1.11]        
6.38 0.85 [0.51, 1.41]        
6.35 0.46 [0.28, 0.77]        
5.44 0.87 [0.45, 1.70]        
1.24 0.13 [0.01, 1.19]        
85.75 0.61 [0.46, 0.80]
100.00 0.61 [0.47, 0.79]
0.5 1 2 5 10
rs DES Favors BMS
) in SVG intervention patients receiving DES compared with those receiving
ith DES. Abbreviations as in Figures 1, 2, 3, and 4.0.2
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1271reviously mentioned, the definition of MACE varied
mong the included studies, which led to heterogeneity
eaching significant levels with some end points. Despite
hat heterogeneity, our analyses effectively summarize
he current practice and provide important insights re-
arding the use of DES in SVG interventions. We
urposefully relied on hard clinical end points rather than
urrogate markers to ensure consistency of the measured
utcomes and support the validity of our conclusions.
onetheless, this heterogeneity might influence the gen-
ralizability of our results. Therefore, large well-designed
andomized studies are still needed to answer this im-
ortant question.
In cohort studies, the type of stent selected for PCI
ight have been influenced by the diameter of the target
essel, because DES might not have been available in
arger sizes. However, the mean vessel diameter in the
ncluded studies is within the available stent diameter
ange in both DES and BMS. Although not identical,
tent diameter (which was included in the analysis) is
enerally similar to vessel diameter, and that did not
nfluence the overall conclusions of the analyses regarding
Study DES BMS
or subcategory n/N n/N
Brilakis, 2009      6/41              12/39        
Jeger, 2009         2/34               0/13        
Vermeersch, 2006    1/38               0/37        
Vermeersch, 2007    7/38               2/37        
Subtotal (95% CI) 151                126
Total events: 16 (DES), 14 (BMS)
Test for heterogeneity: Chi² = 6.22, df = 3 (P = 0.10), I² = 51.8%
Test for overall effect: Z = 0.43 (P = 0.67)
Assali, 2008        6/68               3/43        
Brodie, 2009        93/785             39/343       
Chu, 2006           4/48               2/57        
Ge, 2005            5/61               8/89        
Gioia, 2008         2/106              1/119       
Goswami, 2009       21/284              2/95        
Kaplan, 2008        1/37               5/33        
Lee, 2005           6/139             17/84        
Minutello, 2007     4/59               1/50        
Okabe, 2008         2/138              1/344       
Ramana, 2008        7/141             16/170       
Shishehbor, 2009    16/217              7/110       
van Twisk, 2008     7/122             13/128       
Vignali, 2008       6/72              15/288       
Subtotal (95% CI) 2277               1953
Total events: 180 (DES), 130 (BMS)
Test for heterogeneity: Chi² = 27.12, df = 13 (P = 0.01), I² = 52.1%
Test for overall effect: Z = 0.16 (P = 0.87)
Total (95% CI) 2428               2079
Total events: 196 (DES), 144 (BMS)
Test for heterogeneity: Chi² = 33.31, df = 17 (P = 0.01), I² = 49.0%
Test for overall effect: Z = 0.05 (P = 0.96)
0.1
RCTs
Cohorts
Figure 6. OR of Recurrent MI
Forest plot of unadjusted OR (with 95% CIs) for recurrent myocardial infarction (M
No signiﬁcant difference is observed between the 2 groups. Abbreviations as iLR or TVR.onclusions
ur meta-analysis demonstrates the efficacy and safety of
ES use in SVG interventions. Drug-eluting stent use
as associated with lower rates of TLR, TVR, and
ACE in general, with no evidence of an increased risk
f ST. These results are no substitute for well-designed,
ppropriately powered, randomized trials with long
ollow-up to critically evaluate the long-term outcomes of
ES in SVG interventions.
eprint requests and correspondence: Dr. Khaled M. Ziada,
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